<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Transl Med</journal-id><journal-title>Journal of Translational Medicine</journal-title><issn pub-type="epub">1479-5876</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1479-5876-5-36</article-id><article-id pub-id-type="pmid">17626640</article-id><article-id pub-id-type="doi">10.1186/1479-5876-5-36</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Haplotype of gene Nedd4 binding protein 2 associated with sporadic nasopharyngeal carcinoma in the Southern Chinese population</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Zheng</surname><given-names>Mei-Zhen</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>zhengmeizhen@gmail.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Qin</surname><given-names>Hai-De</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>qinhaide@yahoo.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Yu</surname><given-names>Xing-Juan</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>yuxingjuan@tom.com</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Zhang</surname><given-names>Ru-Hua</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ruhuazhang@yahoo.com.cn</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Chen</surname><given-names>Li-Zhen</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>clz5312@yahoo.com.cn</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Feng</surname><given-names>Qi-Sheng</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>fqsh@tom.com</email></contrib><contrib id="A7" corresp="yes" contrib-type="author"><name><surname>Zeng</surname><given-names>Yi-Xin</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>zengyix@mail.sysu.edu.cn</email></contrib></contrib-group><aff id="I1"><label>1</label>State Key Laboratory of Oncology in Southern China and Department of Experimental Research, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, China</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>13</day><month>7</month><year>2007</year></pub-date><volume>5</volume><fpage>36</fpage><lpage>36</lpage><ext-link ext-link-type="uri" xlink:href="http://www.translational-medicine.com/content/5/1/36"/><history><date date-type="received"><day>6</day><month>5</month><year>2007</year></date><date date-type="accepted"><day>13</day><month>7</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Zheng et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Zheng et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Zheng Mei-Zhen zhengmeizhen@gmail.com </dc:author><dc:title> Haplotype of gene Nedd4 binding protein 2 associated with sporadic nasopharyngeal carcinoma in the Southern Chinese population </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>Journal of Translational Medicine 5(1): 36-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1479-5876(2007)5:1&#x0003c;36&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1479-5876</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Bcl-3 as an oncoprotein is overexpressed in nasopharyngeal carcinoma (NPC). Nedd4 binding protein 2 (N4BP2), which is located in the NPC susceptibility locus, is a Bcl-3 binding protein. This study is aimed to explore the association between N4BP2 genetic polymorphism and the risk of NPC.</p></sec><sec sec-type="methods"><title>Methods</title><p>We performed a hospital-based case-control study, including 531 sporadic NPC and 480 cancer-free control subjects from southern China. PCR-sequencing was carried out on Exons, promoter region and nearby introns of the N4BP2 gene. The expression pattern of N4BP2 and Bcl-3 was also analyzed.</p></sec><sec><title>Results</title><p>We observed a statistically significant difference in haplotype blocks ATTA and GTTG between cases and controls. In addition, three novel SNPs were identified, two of which were in exons (loc123-e3l-snp2, position 39868005, A/G, Met171Val; RS17511668-SNP2, position 39926432, G/A, Glu118Lys), and one was in the intron6 (RS794001-SNP1, position 39944127, T/G). Moreover, N4BP2 was at higher levels in a majority of tumor tissues examined, relative to paired normal tissues.</p></sec><sec><title>Conclusion</title><p>These data suggest that haplotype blocks ATTA and GTTG of N4BP2 is correlation with the risk of sporadic nasopharyngeal carcinoma in the Southern Chinese population and N4BP2 has a potential role in the development of NPC.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Bcl-3 was originally identified as expressed in chronic B cell lymphocytic leukemia [<xref ref-type="bibr" rid="B1">1</xref>]. Many cell growth and survival promoters can induce Bcl-3 expression, and Bcl-3 overexpression has been detected in other cancers such as nasopharyngeal carcinoma (NPC) [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. Nedd4 binding protein 2 (N4BP2, GenBank:<ext-link ext-link-type="gen" xlink:href="AY267013">AY267013</ext-link>) is a Bcl-3 binding protein, N4BP2 protein contains a polynucleotide kinase domain (PNK) at the N-terminus and a Small MutS Related (Smr) domain with nicking endonuclease activity near C-terminus [<xref ref-type="bibr" rid="B3">3</xref>]. MutS is central to the DNA mismatch repair (MMR) systems that are responsible for maintaining genome stability and protecting against mutation, Mutations in these genes are linked to the development of certain types of cancer [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. Since N4BP2 contains a MutS-related domain, N4BP2 may play a role in MMR.</p><p>NPC is an epithelial tumor with an exceptionally high incidence in southern China, particularly in the Guangdong province [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. Etiological and epidemiological studies have suggested that susceptibility genes may determine the predisposition to developing NPC [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. Previously, we reported the use of 382 polymorphic microsatellite markers to identify a candidate susceptibility locus that mapped to chromosome 4p15.1-q12 (D4S2950-D4S2916) in a subset of NPC families [<xref ref-type="bibr" rid="B10">10</xref>]. Further analysis identified SNPs within or near this region, strongly suggesting the presence of an NPC susceptibility locus adjacent to the LOC344967 [<xref ref-type="bibr" rid="B11">11</xref>], very close to the <italic>N4BP2 </italic>gene.</p><p>We thus hypothesized that SNPs or other variation in the <italic>N4BP2 </italic>gene lead to a predisposition to developing NPC. We further hypothesized that the <italic>N4BP2 </italic>gene plays a role in tumorigenesis. To address these hypotheses, we examined <italic>N4BP2 </italic>haplotypes among NPC patients from southern China. We also examined mRNA levels of <italic>Bcl-3 </italic>and <italic>N4BP2 </italic>in NPC cell lines and tissues.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Subjects</title><p>A total of 531 sporadic NPC patients and 480 unrelated age, sex-, and geographically-matched healthy individuals from southern China were used for our case-control study. NPC patients were recruited from Sun Yat-sen University Cancer Center and the presence of differentiated non-keratinizing NPC or undifferentiated NPC was confirmed by histological analysis. Control subjects were recruited from the People's Hospital of Guangdong Province. The characteristics of cases and controls are shown in Table <xref ref-type="table" rid="T1">1</xref>. Although the incidence of NPC is generally higher among males than females, no significant difference in sex distribution existed between case and control groups in this study. The average age in the control group was 37 &#x000b1; 10, and in the case group was 40 &#x000b1; 10; thus the age distribution here is a good representation of the broader NPC patient population given that NPC incidence peaks at the relatively young age of 45.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Profile of the study subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Characteristic</td><td align="left">Control (n = 480)</td><td align="left">Case (n = 531)</td><td align="left">Chi square</td><td align="left"><italic>p</italic><sup>a</sup></td></tr></thead><tbody><tr><td align="left">Gender (Male/Female)</td><td align="left">354/126</td><td align="left">390/141</td><td align="left">0.01</td><td align="left">0.91</td></tr><tr><td align="left">Age</td><td align="left">37 &#x000b1; 10</td><td align="left">40 &#x000b1; 10</td><td align="left">0.86</td><td align="left">0.44</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup><italic>p </italic>value obtained from Chi-square Test</p></table-wrap-foot></table-wrap></sec><sec><title>DNA preparation</title><p>Genomic DNA was extracted from 5&#x02013;10 ml peripheral blood using the QIAamp DNA Blood Midi kit (Qiagen, German).</p></sec><sec><title>Primer design</title><p>Between 250 and 400 bp of sequence surrounding SNPs sites were submitted to the primer design program [<xref ref-type="bibr" rid="B12">12</xref>]. The primers used for SNPs are shown in Table <xref ref-type="table" rid="T2">2</xref>.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Primers used for SNPs</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Number</td><td align="left">RefSNP(RS) (NCBI)</td><td align="left">Forward primers(5'&#x02192;3')</td><td align="left">Reverse primer(5'&#x02192;3')</td><td align="left">Product size (bp)</td></tr></thead><tbody><tr><td align="left">SNP1</td><td align="left">RS17439810</td><td align="left">agctgacagtgttcggctct</td><td align="left">ggtcaacatgatgtccgaaa</td><td align="left">257</td></tr><tr><td align="left">SNP2</td><td align="left">loc123-e3l-snp2<sup>a</sup></td><td></td><td></td><td></td></tr><tr><td align="left">SNP3</td><td align="left">RS17511578</td><td align="left">cttctcgtcctgggtctcc</td><td align="left">TGTCAGCTACAGCCAGTCCA</td><td align="left">397</td></tr><tr><td align="left">SNP4</td><td align="left">RS17585937</td><td align="left">acatgggccacaggaagtg</td><td align="left">aggcctgccagacacctg</td><td align="left">266</td></tr><tr><td align="left">SNP6</td><td align="left">RS17511668-SNP2<sup>b</sup></td><td align="left">TCTGTTCAATGCAAAATCCAA</td><td align="left">catcttGTGAAGGCAAAAATGA</td><td align="left">389</td></tr><tr><td align="left">SNP7</td><td align="left">RS794001-SNP1<sup>c</sup></td><td align="left">GCTTCATATATGCCAAGCATCA</td><td align="left">TTTTCTTCTTTTGTTTAAATCTGCATT</td><td align="left">398</td></tr><tr><td align="left">SNP9</td><td align="left">RS2252352</td><td align="left">agaTGCAGCTCAATCACCTA</td><td align="left">CAGAAGAAATTGCCTTACAGGA</td><td align="left">300</td></tr><tr><td align="left">SNP10</td><td align="left">RS2271395</td><td align="left">tccagtctagtcaaaatggtgaga</td><td align="left">aacacacagtgcaatttcttaactg</td><td align="left">243</td></tr><tr><td align="left">SNP11</td><td align="left">RS1442855</td><td align="left">TCATTTGCTTCAGCTTGTCA</td><td align="left">GGCCTTAAACCTTACTCCATCC</td><td align="left">300</td></tr><tr><td align="left">SNP12</td><td align="left">RS2347044</td><td align="left">TCTTGTGGTGAAATGTAGAATGC</td><td align="left">CCTGAGATTAACTACCCATATCAGC</td><td align="left">368</td></tr></tbody></table><table-wrap-foot><p><sup>a </sup>Primers for loc123-e3l-snp2 are same as RS17439810.</p><p><sup>b </sup>primers for RS17511668-SNP2 are same as RS17511668</p><p><sup>c </sup>RS794001-SNP1 are same as RS794001.</p></table-wrap-foot></table-wrap></sec><sec><title>PCR Amplification</title><p>Long-distance PCR was performed in a total volume of 15 &#x003bc;l containing 200 ng of genomic DNA, 1.5 &#x003bc;l 10&#x000d7; Buffer, 50 &#x003bc;M dNTPs, 0.3 &#x003bc;M each primer, and 1U Taq DNA polymerase. Samples were amplified with each pair of primers described above as follows: 94&#x000b0;C for 3 min, 10 cycles of 94&#x000b0;C for 30 s, 63&#x000b0;C for 1 min, and 72&#x000b0;C for 1 min; 25 cycles of 94&#x000b0;C for 30 s, 58&#x000b0;C for 1 min, 72&#x000b0;C for 1 min, and a final extension at 72&#x000b0;C for 7 min. First-round PCR products were diluted 5-fold for the second-round of PCR. Round 2 PCR conditions were 94&#x000b0;C for 3 min, 10 cycles at 94&#x000b0;C for 30 s, 65&#x000b0;C for 1 min, and 72&#x000b0;C for 1 min; 30 cycles at 94&#x000b0;C for 30 s, 62&#x000b0;C for 1 min, and 72&#x000b0;C for 1 min, and 72&#x000b0;C for 7 min. PCR products were visualized on a 1.2% agarose gel, stained with ethidium bromide, and visualized by a transilluminator.</p></sec><sec><title>Genotyping</title><p>PCR products were sequence using ABI377 or ABI3730 sequencers (PE Applied biosystem). Base calling, contig assembly contigs, and mutation detection was performed using Polyphred package (Polyphred, Phred/Phrap/Consed) [<xref ref-type="bibr" rid="B13">13</xref>]. All traces were visually inspected by at least two observers.</p></sec><sec><title>Statistical methods</title><p>Unrelated control samples were selected for analysis using the Hardy-Weinberg Equilibrium (HWE) test using an exact test. Standard EM algorithm was used to infer haplotype and estimate population frequency. Single marker and haplotype association test and significance estimation were performed using a permutation test.</p></sec><sec><title>Cell Culture and Treatment</title><p>NP69 (an SV40 large T antigen-immortalized nasopharyngeal epithelial cell line) and NP69-LMP1 (NP69 cells transfected with the <italic>LMP1 </italic>gene) were cultured in Keratinocyte-SFM medium (GibcoBRL) with Bovine Pituitary Extract and rEGF. C666-1 (a poorly differentiated nasopharyngeal epithelial cell line carrying the Epstein-Barr virus) was grown in RPMI 1640 supplemented with 10% fetal bovine serum (FBS, Hyclone, Utah, USA). CNE-1 (a highly-differentiated nasopharyngeal epithelial cell line), CNE-2 (a poorly differentiated nasopharyngeal epithelial cell line) and Sune(a poorly differentiated nasopharyngeal epithelial cell line carried Epstein-Barr virus) were maintained in RPMI 1640 with 10% FBS.</p></sec><sec><title>Tissue collection and RT-PCR</title><p>A total of 21 tissues were collected from Sun Yat-sen University Cancer Center. Six paired matched tissues from different organs included esophagus, stomach, liver, lung, cervix and breast; nine nasopharyngeal tissues contained 2 chronic nasopharynx inflammation (Inf.), 1 Differentiated Carcinoma (DNK), 4 Undifferentiated Carcinoma (NDNK), 1 low differentiated squamous carcinoma (LDS) and 1 non-Hodgkin's lymphoma (NHL). RNA was extracted using TRIZOL Reagent (Invitrogen, Carlsbad, CA), and reverse transcription was performed using the TaKaRa RNA PCR kit (AMV) Ver.3.0 (TaKaRa BIO, Shiga, Japan). PCR to detect <italic>N4BP2 </italic>was performed using the following primers (<italic>N4BP2-L</italic>: 5'-AAAGGGAGACCCTTATGTTTGA-3'; <italic>N4BP2-R</italic>: 5'-AAATCAAACCTCACTTGCATTT-3') and <italic>Bcl</italic>-3 with primers (<italic>Bcl-3-L</italic>:5'-tcctctggtgaacctgccta-3'; <italic>Bcl-3-R</italic>:5'-gaagaccattggagctgagg-3') and <italic>&#x003b2;-actin </italic>as control with primers (5'-acactgtgcccatctacgagggg-3' and 5'-atgatggagttgaaggtagtttcgtggat-3').</p></sec></sec><sec><title>Results</title><sec><title>SNP analysis</title><p>We identified a total of twelve SNP associated with the <italic>N4BP2 </italic>locus, four of which were upstream of the <italic>N4BP2 </italic>gene and eight which were within <italic>N4BP2 </italic>gene (Table <xref ref-type="table" rid="T3">3</xref>). Of the SNPs, five SNPs resulted in missense mutations. Three novel SNPs were identified: loc123-e3l-snp2 (position 39868005, allele A/G, resulting in amino acid change Met171 to Val), RS17511668-SNP2 (position 39926432, allele G/A, amino acid change Glu118 to Lys), and RS794001-SNP1 (position 39944127, allele T/G, intronic). However, allele frequency analysis revealed no significant difference between case and control groups (Table <xref ref-type="table" rid="T4">4</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Candidate SNPs</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Number</td><td align="left">RefSNP</td><td align="left">Contig Position</td><td align="left">Variant Alleles</td><td align="left">Amino acid change</td><td align="left">MAF</td><td align="left">HWpval</td><td align="left">Genotyped (%)</td></tr></thead><tbody><tr><td align="left">SNP1</td><td align="left">RS17439810</td><td align="left">39867905</td><td align="left">C, G</td><td align="left">Gln104Glu</td><td align="left">0.058</td><td align="left">0.195</td><td align="left">74.0</td></tr><tr><td align="left"><bold>SNP2</bold></td><td align="left"><bold>loc123-e3l-snp2</bold></td><td align="left"><bold>39868005</bold></td><td align="left"><bold>A, G</bold></td><td align="left"><bold>Met171Val</bold></td><td align="left"><bold>0.271</bold></td><td align="left"><bold>0.999</bold></td><td align="left"><bold>81.4</bold></td></tr><tr><td align="left">SNP3</td><td align="left">RS17511578</td><td align="left">39868252</td><td align="left">A, C</td><td align="left">Asn189His</td><td align="left">0.063</td><td align="left">0.978</td><td align="left">74.8</td></tr><tr><td align="left">SNP4</td><td align="left">RS17585937</td><td align="left">39868402</td><td align="left">G, A</td><td align="left">5'UTR</td><td align="left">0.118</td><td align="left">1.000</td><td align="left">76.2</td></tr><tr><td align="left"><bold>SNP6</bold></td><td align="left"><bold>RS17511668-SNP2</bold></td><td align="left"><bold>39926432</bold></td><td align="left"><bold>G, A</bold></td><td align="left"><bold>Glu118Lys</bold></td><td align="left"><bold>0.067</bold></td><td align="left"><bold>1.000</bold></td><td align="left"><bold>89.9</bold></td></tr><tr><td align="left"><bold>SNP7</bold></td><td align="left"><bold>RS794001-SNP1</bold></td><td align="left"><bold>39944127</bold></td><td align="left"><bold>T, G</bold></td><td align="left"><bold>intron</bold></td><td align="left"><bold>0.054</bold></td><td align="left"><bold>0.562</bold></td><td align="left"><bold>97.4</bold></td></tr><tr><td align="left">SNP9</td><td align="left">RS2252352</td><td align="left">39950655</td><td align="left">T, T</td><td align="left">intron</td><td align="left">0.368</td><td align="left">0.327</td><td align="left">96.1</td></tr><tr><td align="left">SNP10</td><td align="left">RS2271395</td><td align="left">39961241</td><td align="left">G, A</td><td align="left">Ala1587Thr</td><td align="left">0.368</td><td align="left">1.000</td><td align="left">94.8</td></tr><tr><td align="left">SNP11</td><td align="left">RS1442855</td><td align="left">43164843</td><td align="left">G, A</td><td align="left">intron</td><td align="left">0.164</td><td align="left">0.946</td><td align="left">82.5</td></tr><tr><td align="left">SNP12</td><td align="left">RS2347044</td><td align="left">43273849</td><td align="left">A, G</td><td align="left">intron</td><td align="left">0.225</td><td align="left">0.377</td><td align="left">96.9</td></tr></tbody></table><table-wrap-foot><p>RefSNP(RS), SNP accession ID; HWpval, <italic>P </italic>value of Hardy-Weinberg equilibrium tests for control subjects; MAF, minor allele frequency; % Genotyped, Percent of samples successfully genotyped. New SNPs are shown in bold.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>SNP allele frequency comparison between cases and controls</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Number</td><td align="left">Name</td><td align="left">Major Alleles</td><td align="left">Case, Control Ratios<sup>a</sup></td><td align="left">Chi square</td><td align="left">P value</td></tr></thead><tbody><tr><td align="left">SNP1</td><td align="left">loc123-e3l-snp1</td><td align="left">C, C</td><td align="left">772:42 452:34</td><td align="left">1.864</td><td align="left">0.1722</td></tr><tr><td align="left">SNP2</td><td align="left">loc123-e3l-snp2</td><td align="left">A, A</td><td align="left">570:224 472:164</td><td align="left">1.051</td><td align="left">0.3053</td></tr><tr><td align="left">SNP3</td><td align="left">loc123-e3l-snp3</td><td align="left">G, G</td><td align="left">659:51 572:32</td><td align="left">1.960</td><td align="left">0.1615</td></tr><tr><td align="left">SNP4</td><td align="left">LOC344967</td><td align="left">G, G</td><td align="left">634:74 546:84</td><td align="left">2.658</td><td align="left">0.1031</td></tr><tr><td align="left">SNP6</td><td align="left">RS17511668-SNP2</td><td align="left">G, G</td><td align="left">802:66 670:40</td><td align="left">2.419</td><td align="left">0.1199</td></tr><tr><td align="left">SNP7</td><td align="left">RS794001-SNP1</td><td align="left">T, T</td><td align="left">890:48 728:44</td><td align="left">0.282</td><td align="left">0.5954</td></tr><tr><td align="left">SNP9</td><td align="left">RS2252352</td><td align="left">T, T</td><td align="left">574:320 493:301</td><td align="left">0.809</td><td align="left">0.3684</td></tr><tr><td align="left">SNP 10</td><td align="left">RS2271395</td><td align="left">A, A</td><td align="left">599:331 452:282</td><td align="left">1.410</td><td align="left">0.2350</td></tr><tr><td align="left">SNP 11</td><td align="left">RS1442855</td><td align="left">G, G</td><td align="left">646:128 565:109</td><td align="left">0.035</td><td align="left">0.8513</td></tr><tr><td align="left">SNP 12</td><td align="left">RS2347044</td><td align="left">A, A</td><td align="left">712:212 607:171</td><td align="left">0.225</td><td align="left">0.6351</td></tr></tbody></table><table-wrap-foot><p><sup>a </sup>Case, Control Ratios = the frequency of Major Alleles: the frequency of Minor Alleles</p></table-wrap-foot></table-wrap></sec><sec><title>Haplotype analysis</title><p>Haplotype frequencies and distributions were estimated using a standard EM algorithm. Interestingly, Four SNPs (SNP6-7-9-10) combined haplotype Block 2 ATTA and GTTG exhibited notable difference between case and control groups (Table <xref ref-type="table" rid="T5">5</xref>). Permutation tests for allelic association confirmed that block ATTA and GTTG are closely linked (Table <xref ref-type="table" rid="T6">6</xref>) and confirmed the difference of Block 2 ATTA and GTTG in cases and controls.</p><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Haplotype analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Block</td><td align="left">Haplotype</td><td align="left">Frequencies<sup>a</sup></td><td align="center">Case, Control Ratios<sup>b</sup></td><td align="left">Chi Square</td><td align="left">P Value</td></tr></thead><tbody><tr><td align="left">1(SNP1-4)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td align="left">CAG</td><td align="left">0.55</td><td align="center">519.0:411.0, 420.2:357.8</td><td align="left">0.557</td><td align="left">0.4556</td></tr><tr><td></td><td align="left">CGG</td><td align="left">0.272</td><td align="center">261.2:668.8, 204.2:573.8</td><td align="left">0.724</td><td align="left">0.3947</td></tr><tr><td></td><td align="left">CAA</td><td align="left">0.119</td><td align="center">100.6:829.4, 103.0:675.0</td><td align="left">2.368</td><td align="left">0.1238</td></tr><tr><td></td><td align="left">GAG</td><td align="left">0.058</td><td align="center">49.2:880.8, 50.6:727.4</td><td align="left">1.149</td><td align="left">0.2837</td></tr><tr><td align="left">2(SNP6-7-9-10)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td align="left">GTTA</td><td align="left">0.542</td><td align="center">521.4:426.6, 429.0:377.0</td><td align="left">0.549</td><td align="left">0.4589</td></tr><tr><td></td><td align="left">GTCG</td><td align="left">0.355</td><td align="center">328.2:619.8, 294.3:511.7</td><td align="left">0.684</td><td align="left">0.4082</td></tr><tr><td></td><td align="left">AGTA</td><td align="left">0.047</td><td align="center">40.4:907.6, 41.6:764.4</td><td align="left">0.806</td><td align="left">0.3692</td></tr><tr><td></td><td align="left"><bold>ATTA</bold></td><td align="left"><bold>0.017</bold></td><td align="center"><bold>27.4:920.6, 2.7:803.3</bold></td><td align="left"><bold>16.903</bold></td><td align="left"><bold>3.93E-05</bold></td></tr><tr><td></td><td align="left"><bold>GTTG</bold></td><td align="left"><bold>0.016</bold></td><td align="center"><bold>4.6:943.4, 23.3:782.7</bold></td><td align="left"><bold>16.038</bold></td><td align="left"><bold>6.21E-05</bold></td></tr><tr><td></td><td align="left">GTCA</td><td align="left">0.015</td><td align="center">13.1:934.9, 12.9:793.1</td><td align="left">0.14</td><td align="left">0.7079</td></tr></tbody></table><table-wrap-foot><p>Bold type indicates significant difference between case and control.</p><p><sup>a </sup>frequency of haplotype in total subjects.</p><p><sup>b</sup>frequency of haplotype: frequency of non-haplotype.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T6"><label>Table 6</label><caption><p>Permutation test</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Name</td><td align="left">Chi Square</td><td align="left">Permutation p-value</td></tr></thead><tbody><tr><td align="left"><bold>Block 2: ATTA</bold></td><td align="left"><bold>16.903</bold></td><td align="left"><bold>0.0007</bold></td></tr><tr><td align="left"><bold>Block 2: GTTG</bold></td><td align="left"><bold>16.038</bold></td><td align="left"><bold>0.0013</bold></td></tr><tr><td align="left">Block 1: CAA</td><td align="left">2.368</td><td align="left">0.8602</td></tr><tr><td align="left">Block 1: GAG</td><td align="left">1.149</td><td align="left">0.9916</td></tr><tr><td align="left">Block 2: AGTA</td><td align="left">0.806</td><td align="left">0.9992</td></tr><tr><td align="left">Block 1: CGG</td><td align="left">0.724</td><td align="left">0.9997</td></tr><tr><td align="left">Block 2: GTCG</td><td align="left">0.684</td><td align="left">0.9998</td></tr><tr><td align="left">Block 1: CAG</td><td align="left">0.557</td><td align="left">1</td></tr><tr><td align="left">Block 2: GTTA</td><td align="left">0.549</td><td align="left">1</td></tr><tr><td align="left">Block 2: GTCA</td><td align="left">0.14</td><td align="left">1</td></tr><tr><td></td><td></td><td></td></tr><tr><td align="left">LOC344967</td><td align="left">2.658</td><td align="left">0.8071</td></tr><tr><td align="left">RS17511668-SNP2</td><td align="left">2.419</td><td align="left">0.8498</td></tr><tr><td align="left">loc123-e3l-snp3</td><td align="left">1.96</td><td align="left">0.9218</td></tr><tr><td align="left">loc123-e3l-snp1</td><td align="left">1.864</td><td align="left">0.9366</td></tr><tr><td align="left">RS2271395</td><td align="left">1.41</td><td align="left">0.9807</td></tr><tr><td align="left">loc123-e3l-snp2</td><td align="left">1.051</td><td align="left">0.9952</td></tr><tr><td align="left">RS2252352</td><td align="left">0.809</td><td align="left">0.9991</td></tr><tr><td align="left">RS794001-SNP1</td><td align="left">0.282</td><td align="left">1</td></tr><tr><td align="left">RS1442855</td><td align="left">0.035</td><td align="left">1</td></tr><tr><td align="left">RS2347044</td><td align="left">0.225</td><td align="left">1</td></tr><tr><td align="left" colspan="3">10000 permutations performed.</td></tr></tbody></table><table-wrap-foot><p>Haplotype in bold is closely linked block</p></table-wrap-foot></table-wrap></sec><sec><title>N4BP2 and Bcl-3 expressed in cells and tissues</title><p><italic>Bcl-3 </italic>and <italic>N4BP2 </italic>were detected in all cell lines examined (Figure <xref ref-type="fig" rid="F1">1A</xref>). Interestingly, gene expression levels appeared to vary among the cell lines, with the lowest levels being detected in the Sune line. <italic>N4BP2 </italic>and <italic>Bcl-3 </italic>mRNA levels appeared to be higher in tumor than in matched normal tissue (Figure <xref ref-type="fig" rid="F1">1B</xref>). <italic>N4BP2 </italic>and <italic>Bcl-3 </italic>were also detected in nasopharyngeal tissues (Figure <xref ref-type="fig" rid="F1">1C</xref>). These observations suggest that <italic>N4BP2 </italic>expression levels correlate with the progression of cancer including NPC.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Expression of <italic>N4BP2 </italic>and <italic>Bcl-3 </italic>mRNA in cells and tissues</bold>. (A) Expression of <italic>N4BP2 </italic>and <italic>Bcl-3 </italic>mRNA in nasopharyngeal epithelial cell lines. RT-PCR was performed with gene-specific primers and <italic>&#x003b2;-actin </italic>was used as a control. (B) Expression of <italic>N4BP2 </italic>and <italic>Bcl-3 </italic>mRNA in matched tissues. RT-PCR was performed with gene-specific primers and <italic>&#x003b2;-actin </italic>as a control. up-low: normal tissue; down-low: tumor tissue. (C) Expression of <italic>N4BP2 </italic>and <italic>Bcl-3 </italic>mRNA nasopharyngeal tissues. Inf.: chronic nasopharynx inflammation; NDNK: Undifferentiated Carcinoma; DNK: Differentiated Carcinoma; LDS: Low differentiated squamous carcinoma; NHL: non-Hodgkin's lymphoma.</p></caption><graphic xlink:href="1479-5876-5-36-1"/></fig></sec></sec><sec><title>Discussion</title><p>We previously showed, by linkage analysis that an NPC susceptibility locus maps to chromosome 4 near the <italic>LOC344967</italic>. Here, we extend this analysis in an effort to identify a bona fide NPC susceptibility gene. <italic>N4BP2 </italic>is a candidate gene in this region, and we thus sought to examine the correlation between genetic polymorphisms in <italic>N4BP2</italic>, a mismatch repair gene, and the incidence of NPC. SNPs have been shown to be extremely useful for studying the association between genomic regions and disease [<xref ref-type="bibr" rid="B14">14</xref>]. Several studies have demonstrated that polymorphic variation in mismatch repair genes contributes to susceptibility to certain cancers [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. In addition, several pieces of evidence suggest that nasopharyngeal carcinogenesis is associated with individual susceptibility caused by SNPs. Our results show that, although there is no significant difference in SNPs between cases and controls, there are two haplotypes, ATTA and GTTG, the distribution of which differed between case and control groups. Just as the report that almost not any difference in the allele frequencies of five SNPs within the <italic>TNFSF4 </italic>gene individuals suffered from coronary artery disease versus the controls while there were significantly more frequent of the possible haplotypes from this five TNFSF4 SNPs in individuals with coronary artery disease than controls [<xref ref-type="bibr" rid="B17">17</xref>]. Insight into this paradox has been provided in a recent review by Schaid [<xref ref-type="bibr" rid="B18">18</xref>]. Haplotypes, the grouping of closely linked alleles on a chromosome, make an important contribution to the study of the genetic basis of disease. Schaid [<xref ref-type="bibr" rid="B18">18</xref>] explained that for case-control studies, methodological approach based on haplotype has more advantage than single-locus analysis as the SNPs are in LD with a causative diallelic locus; in particular, haplotype-based methods have greater power when the marker alleles are in strong LD with causative alleles. Haplotype methods are more useful for variants which are more recently evolved, rarer and more causative than for variants which are older and more common. This may help explain why the haplotypes ATTA and GTTG exhibit differences in frequency between case and control groups while individual SNPs do not.</p><p>N4BP2 is a Bcl-3 binding protein, and Bcl-3 is an oncoprotein that is overexpressed in certain cancers, including NPC. Our analysis of <italic>N4BP2 </italic>and <italic>Bcl-3 </italic>expression levels suggest that expression of these genes is correlated, suggesting they may be co-regulated. We also found that <italic>N4BP2 </italic>and <italic>Bcl-3 </italic>are expressed in all NPC cell lines examined and were higher for certain cancers. These observations are consistent with previous reports.</p></sec><sec><title>Conclusion</title><p>Above all, we found that two <italic>N4BP2 </italic>haplotypes, ATTA and GTTG, are correlated with NPC. This will be useful for predict the development of NPC. In addition, <italic>N4BP2 </italic>and <italic>Bcl-3 </italic>mRNA levels were elevated in tumors, including NPC tumors, which suggest new therapeutic targets for fighting NPC.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>YXZ and HDQ were responsible for the design of study. MZZ carried out the experiments and drafted the manuscript. HDQ participated in data analysis. XJY and RHZ performed sequencing. LZC and QSF helped in cell culture and tissue collection.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported by grants from the Natural Science Foundation of Guangdong Province, China (No. A1080202), the National High Technology Research and Development Program of China (863 Program) (No. 2001AA221171) and the Major State Basic Research Development Program of China (973 Program) (No. G1998051201).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McKeithan</surname><given-names>T</given-names></name><name><surname>Ohno</surname><given-names>H</given-names></name><name><surname>Rowley</surname><given-names>J</given-names></name><name><surname>Diaz</surname><given-names>M</given-names></name></person-group><article-title>Cloning of the breakpoint junction of the translocation 14;19 in chronic lymphocytic leukemia</article-title><source>Haematol Blood Transfus</source><year>1989</year><volume>32</volume><fpage>335</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">2625254</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thornburg</surname><given-names>NJ</given-names></name><name><surname>Pathmanathan</surname><given-names>R</given-names></name><name><surname>Raab-Traub</surname><given-names>N</given-names></name></person-group><article-title>Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>8293</fpage><lpage>8301</lpage><pub-id pub-id-type="pmid">14678988</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>N</given-names></name><name><surname>Wachi</surname><given-names>S</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name></person-group><article-title>Identification and characterization of BCL-3-binding protein: implications for transcription and DNA repair or recombination</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>26102</fpage><lpage>26110</lpage><pub-id pub-id-type="pmid">12730195</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M303518200</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lamers</surname><given-names>MH</given-names></name><name><surname>Perrakis</surname><given-names>A</given-names></name><name><surname>Enzlin</surname><given-names>JH</given-names></name><name><surname>Winterwerp</surname><given-names>HH</given-names></name><name><surname>de Wind</surname><given-names>N</given-names></name><name><surname>Sixma</surname><given-names>TK</given-names></name></person-group><article-title>The crystal structure of DNA mismatch repair protein MutS binding to a G &#x000d7; T mismatch</article-title><source>Nature</source><year>2000</year><volume>407</volume><fpage>711</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">11048711</pub-id><pub-id pub-id-type="doi">10.1038/35037523</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Obmolova</surname><given-names>G</given-names></name><name><surname>Ban</surname><given-names>C</given-names></name><name><surname>Hsieh</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name></person-group><article-title>Crystal structures of mismatch repair protein MutS and its complex with a substrate DNA</article-title><source>Nature</source><year>2000</year><volume>407</volume><fpage>703</fpage><lpage>710</lpage><pub-id pub-id-type="pmid">11048710</pub-id><pub-id pub-id-type="doi">10.1038/35037509</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>DL</given-names></name><name><surname>Huang</surname><given-names>TB</given-names></name></person-group><article-title>A case-control study of risk factors of nasopharyngeal carcinoma</article-title><source>Cancer Lett</source><year>1997</year><volume>117</volume><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">9233826</pub-id><pub-id pub-id-type="doi">10.1016/S0304-3835(97)00182-1</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>JL</given-names></name><name><surname>Glaser</surname><given-names>SL</given-names></name></person-group><article-title>Epstein-barr virus-associated malignancies: epidemiologic patterns and etiologic implications</article-title><source>Crit Rev Oncol Hematol</source><year>2000</year><volume>34</volume><fpage>27</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">10781747</pub-id><pub-id pub-id-type="doi">10.1016/S1040-8428(00)00046-9</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hildesheim</surname><given-names>A</given-names></name><name><surname>Dosemeci</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>CC</given-names></name><name><surname>Chen</surname><given-names>CJ</given-names></name><name><surname>Cheng</surname><given-names>YJ</given-names></name><name><surname>Hsu</surname><given-names>MM</given-names></name><name><surname>Chen</surname><given-names>IH</given-names></name><name><surname>Mittl</surname><given-names>BF</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><name><surname>Levine</surname><given-names>PH</given-names></name><name><surname>Chen</surname><given-names>JY</given-names></name><name><surname>Brinton</surname><given-names>LA</given-names></name><name><surname>Yang</surname><given-names>CS</given-names></name></person-group><article-title>Occupational exposure to wood, formaldehyde, and solvents and risk of nasopharyngeal carcinoma</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2001</year><volume>10</volume><fpage>1145</fpage><lpage>1153</lpage><pub-id pub-id-type="pmid">11700262</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>YJ</given-names></name><name><surname>Hildesheim</surname><given-names>A</given-names></name><name><surname>Hsu</surname><given-names>MM</given-names></name><name><surname>Chen</surname><given-names>IH</given-names></name><name><surname>Brinton</surname><given-names>LA</given-names></name><name><surname>Levine</surname><given-names>PH</given-names></name><name><surname>Chen</surname><given-names>CJ</given-names></name><name><surname>Yang</surname><given-names>CS</given-names></name></person-group><article-title>Cigarette smoking, alcohol consumption and risk of nasopharyngeal carcinoma in Taiwan</article-title><source>Cancer Causes Control</source><year>1999</year><volume>10</volume><fpage>201</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">10454065</pub-id><pub-id pub-id-type="doi">10.1023/A:1008893109257</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>BJ</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Shugart</surname><given-names>YY</given-names></name><name><surname>Lee</surname><given-names>MK</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Xia</surname><given-names>JC</given-names></name><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Huang</surname><given-names>TB</given-names></name><name><surname>Jian</surname><given-names>SW</given-names></name><name><surname>Huang</surname><given-names>P</given-names></name><name><surname>Feng</surname><given-names>QS</given-names></name><name><surname>Huang</surname><given-names>LX</given-names></name><name><surname>Yu</surname><given-names>XJ</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>LZ</given-names></name><name><surname>Jia</surname><given-names>WH</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>HM</given-names></name><name><surname>Zhu</surname><given-names>JL</given-names></name><name><surname>Liu</surname><given-names>XM</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>WQ</given-names></name><name><surname>Deng</surname><given-names>MQ</given-names></name><name><surname>Hu</surname><given-names>WH</given-names></name><name><surname>Wu</surname><given-names>SX</given-names></name><name><surname>Mo</surname><given-names>HY</given-names></name><name><surname>Hong</surname><given-names>MF</given-names></name><name><surname>King</surname><given-names>MC</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Zeng</surname><given-names>YX</given-names></name></person-group><article-title>Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4</article-title><source>Nat Genet</source><year>2002</year><volume>31</volume><fpage>395</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">12118254</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>RC</given-names></name><name><surname>Qin</surname><given-names>HD</given-names></name><name><surname>Zeng</surname><given-names>MS</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Feng</surname><given-names>BJ</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>HK</given-names></name><name><surname>Jia</surname><given-names>WH</given-names></name><name><surname>Chen</surname><given-names>LZ</given-names></name><name><surname>Feng</surname><given-names>QS</given-names></name><name><surname>Zhang</surname><given-names>RH</given-names></name><name><surname>Yu</surname><given-names>XJ</given-names></name><name><surname>Zheng</surname><given-names>MZ</given-names></name><name><surname>Zeng</surname><given-names>YX</given-names></name></person-group><article-title>A functional variant in the transcriptional regulatory region of gene LOC344967 cosegregates with disease phenotype in familial nasopharyngeal carcinoma</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>693</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">16423998</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2166</pub-id></citation></ref><ref id="B12"><citation citation-type="other"><article-title>Primer3</article-title><ext-link ext-link-type="uri" xlink:href="http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi"/></citation></ref><ref id="B13"><citation citation-type="other"><article-title>Department of genome sciences university of Washington</article-title><ext-link ext-link-type="uri" xlink:href="http://droog.gs.washington.edu/"/></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kwok</surname><given-names>PY</given-names></name><name><surname>Gu</surname><given-names>Z</given-names></name></person-group><article-title>Single nucleotide polymorphism libraries: why and how are we building them?</article-title><source>Mol Med Today</source><year>1999</year><volume>5</volume><fpage>538</fpage><lpage>543</lpage><pub-id pub-id-type="pmid">10562720</pub-id><pub-id pub-id-type="doi">10.1016/S1357-4310(99)01601-9</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawakami</surname><given-names>T</given-names></name><name><surname>Shiina</surname><given-names>H</given-names></name><name><surname>Igawa</surname><given-names>M</given-names></name><name><surname>Deguchi</surname><given-names>M</given-names></name><name><surname>Nakajima</surname><given-names>K</given-names></name><name><surname>Ogishima</surname><given-names>T</given-names></name><name><surname>Tokizane</surname><given-names>T</given-names></name><name><surname>Urakami</surname><given-names>S</given-names></name><name><surname>Enokida</surname><given-names>H</given-names></name><name><surname>Miura</surname><given-names>K</given-names></name><name><surname>Ishii</surname><given-names>N</given-names></name><name><surname>Kane</surname><given-names>CJ</given-names></name><name><surname>Carroll</surname><given-names>PR</given-names></name><name><surname>Dahiya</surname><given-names>R</given-names></name></person-group><article-title>Inactivation of the hMSH3 mismatch repair gene in bladder cancer</article-title><source>Biochem Biophys Res Commun</source><year>2004</year><volume>325</volume><fpage>934</fpage><lpage>942</lpage><pub-id pub-id-type="pmid">15541380</pub-id><pub-id pub-id-type="doi">10.1016/j.bbrc.2004.10.114</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Apessos</surname><given-names>A</given-names></name><name><surname>Mihalatos</surname><given-names>M</given-names></name><name><surname>Danielidis</surname><given-names>I</given-names></name><name><surname>Kallimanis</surname><given-names>G</given-names></name><name><surname>Agnantis</surname><given-names>NJ</given-names></name><name><surname>Triantafillidis</surname><given-names>JK</given-names></name><name><surname>Fountzilas</surname><given-names>G</given-names></name><name><surname>Kosmidis</surname><given-names>PA</given-names></name><name><surname>Razis</surname><given-names>E</given-names></name><name><surname>Georgoulias</surname><given-names>VA</given-names></name><name><surname>Nasioulas</surname><given-names>G</given-names></name></person-group><article-title>hMSH2 is the most commonly mutated MMR gene in a cohort of Greek HNPCC patients</article-title><source>Br J Cancer</source><year>2005</year><volume>92</volume><fpage>396</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">15655560</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Ria</surname><given-names>M</given-names></name><name><surname>Kelmenson</surname><given-names>PM</given-names></name><name><surname>Eriksson</surname><given-names>P</given-names></name><name><surname>Higgins</surname><given-names>DC</given-names></name><name><surname>Samneg&#x000e5;rd</surname><given-names>A</given-names></name><name><surname>Petros</surname><given-names>C</given-names></name><name><surname>Rollins</surname><given-names>J</given-names></name><name><surname>Bennet</surname><given-names>AM</given-names></name><name><surname>Wiman</surname><given-names>B</given-names></name><name><surname>de Faire</surname><given-names>U</given-names></name><name><surname>Wennberg</surname><given-names>C</given-names></name><name><surname>Olsson</surname><given-names>PG</given-names></name><name><surname>Ishii</surname><given-names>N</given-names></name><name><surname>Sugamura</surname><given-names>K</given-names></name><name><surname>Hamsten</surname><given-names>A</given-names></name><name><surname>Forsman-Semb</surname><given-names>K</given-names></name><name><surname>Lagercrantz</surname><given-names>J</given-names></name><name><surname>Paigen</surname><given-names>B</given-names></name></person-group><article-title>Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><fpage>365</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">15750594</pub-id><pub-id pub-id-type="doi">10.1038/ng1524</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schaid</surname><given-names>DJ</given-names></name></person-group><article-title>Evaluating associations of haplotypes with traits</article-title><source>Genet Epidemiol</source><year>2004</year><volume>27</volume><fpage>348</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">15543638</pub-id><pub-id pub-id-type="doi">10.1002/gepi.20037</pub-id></citation></ref></ref-list></back></article> 